This pattern of increased protein marker expression extends beyond CD81, as shown by Tian et al., who reported higher abundance levels of CD63 in EVs from metastatic breast cancer patients compared to non-metastatic breast cancer patients and healthy donors. This evidence concerns the gene CD81 and breast carcinoma.